The "Magnificent 7" Are Lagging the Market — and That's Healthy
Mega-cap tech is down 2% while small caps surge 23% and emerging markets 24%. The great broadening of 2026 is underway.
For three years, U.S. stock returns were essentially a bet on seven companies. In 2026, that trade has quietly inverted: the "Magnificent 7" are down about 2% even as the S&P 500 gains 10%, small-cap stocks surge 23%, and emerging markets rally 24%.
It is the broadest equity market in years — and many strategists argue it is the healthiest.
What changed
Two forces are at work. First, investors have begun questioning the sheer scale of AI data-center spending, which now exceeds the operating cash flow of the hyperscalers funding it. Massive capex without visible margin payoff compresses the premium investors will pay. Second, the rest of the market finally has stories of its own: semiconductors beyond the giants, industrials wiring the power grid for AI, and international markets enjoying currency and commodity tailwinds — commodities themselves are up 14% this year.
What it means for portfolios
Concentration risk is unwinding. An equal-weight index, left for dead in 2024, is finally earning its keep, and diversification is being rewarded rather than punished. The lesson is not that big tech is broken — margins remain near records — but that the market has stopped pricing seven companies as the only future. Bull markets that broaden tend to last longer than bull markets that narrow.
